Higher rates of carbapenem-related seizures in older hospitalised adults

Intern Med J. 2020 Jan;50(1):123-127. doi: 10.1111/imj.14693.

Abstract

Clinical experience suggests higher occurrence of carbapenem-associated seizures in the elderly than what is reported in the available literature (range between 0.2% and 0.7%). An audit of 1345 patients with age 60 years or older, who received imipenem, ertapenem or meropenem during their acute hospitalisation found 32 (2.4%) subjects developed seizures. Subjects with more than one central nervous system disorders were 11.6 times more likely to develop seizures (odds ratio 11.61, P < 0.001) and subjects with prior history of seizures is associated with four times greater risks (odds ratio 4.02, P = 0.005). Physicians should exercise caution when prescribing carbapenems in elderly, especially those with known epilepsy and a high number of intracranial pathologies.

Keywords: carbapenem; elderly; seizure.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents / adverse effects*
  • Carbapenems / adverse effects*
  • Ertapenem / adverse effects
  • Female
  • Hospitalization
  • Humans
  • Imipenem / adverse effects
  • Logistic Models
  • Male
  • Meropenem / adverse effects
  • Seizures / chemically induced*
  • Seizures / epidemiology*
  • Singapore / epidemiology
  • beta-Lactams / adverse effects

Substances

  • Anti-Bacterial Agents
  • Carbapenems
  • beta-Lactams
  • Imipenem
  • Meropenem
  • Ertapenem